Biotech RadarJobs updated

COMPANY

CicloMed LLC

HQ: Kansas City, MO source · ciclomed.com ↗ · Midwest

Clinical Phase 2

Also known as CicloMed · 6 sources

Keywords: oncology urinary bladder cancer non-muscle invasive bladder cancer Refractory Acute Myeloid Leukemia Recurrent Acute Myeloid Leukemia

Location: Kansas City, MO · source · Oct 15, 2026

Profile checked Oct 10, 2026

4Trials (company is sponsor)2NIH grants

Timeline

  1. Trial start Phase 1/Phase 2: Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia source ↗
  2. Trial start Phase 2: Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors source ↗
  3. Trial start Phase 1: Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors source ↗
  4. Trial start Phase 1: Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors source ↗

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT04608045Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid TumorsPhase 1CompletedMay 19, 2019Apr 30, 2023 (actual)
NCT04525131Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder TumorsPhase 2CompletedNov 25, 2020Dec 30, 2022 (actual)
NCT04956042Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid LeukemiaPhase 1/Phase 2TerminatedAug 27, 2021Dec 31, 2023 (actual)
NCT03348514Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid TumorsPhase 1CompletedJan 15, 2018May 31, 2020 (actual)

NIH awards 2

Annual award amounts. Total $1.9M.

Feedback